Navigation Links
Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Metaglip(R)
Date:1/14/2008

DETROIT, Jan. 14 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd., (Amex: CPD) announced today that the US Food and Drug Administration (FDA) has granted final approval for the Company's Abbreviated New Drug Application (ANDA) for Glipizide/Metformin Hydrochloride Tablets, 2.5/250 mg, 2.5/500 mg and 5/500 mg (Glipizide/Metformin HCl).

Glipizide/Metformin HCl is indicated as initial therapy, as an adjunct to diet and exercise, to improve glycemic control in patients with type 2 diabetes whose hyperglycemia cannot be satisfactorily managed with diet and exercise alone. It is also indicated as second-line therapy when diet, exercise, and initial treatment with a sulfonylurea or metformin do not result in adequate glycemic control in patients with type 2 diabetes. Our generic Glipizide/Metformin HCl is the bioequivalent to Metaglip(R), a registered trademark of Bristol-Myers Squibb Company. According to IMS Data, for the twelve months ended September 2007, Glipizide/Metformin HCl generic and brand products (Metaglip(R)) combined had annual sales of approximately $25 million.

Daniel H. Movens, Caraco's Chief Executive Officer, said, "We are pleased to gain this approval from the FDA. Our focus continues to be working towards expanding our product line effectively, including products that are already available generically in the market that potentially can add measurable value."

Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures, markets and distributes generic and private-label pharmaceuticals to the nation's largest wholesalers, distributors, drugstore chains and managed care providers.

Safe Harbor: This news release contains forward-looking statements made pursuant to t
'/>"/>

SOURCE Caraco Pharmaceutical Laboratories, Ltd.,
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
2. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
4. Caraco Pharmaceutical Laboratories Ltd. Announces Tentative FDA Approval for Generic Zyrtec Chewable(R)
5. Caraco Pharmaceutical Laboratories Ltd. Reports Record Net Sales for the Second Quarter and First Six Months of Fiscal 2008
6. Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval for Generic Lamictal(R)
7. Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval for Generic Lexapro(R)
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Norvasc(R)
9. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Zyrtec Allergy Tablets(R) and Zyrtec Hives Relief Tablets(R)
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Childrens Zyrtec(R) Chewable Tablets for Allergy Relief and Childrens Zyrtec(R) Chewable Tablets for Hives Relief
11. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2015)... Watertown, MA (PRWEB) , ... August 31, 2015 ... ... ChopChop Magazine: The Fun Cooking Magazine for Kids , recently elected two ... ChopChop’s bylaws. These appointments will further ChopChop’s mission of inspiring and teaching kids ...
(Date:8/30/2015)... ... ... Scientists in France say asbestos exposure may put workers at higher risk ... just posted an article on the new research. Click here to read it ... 2,024 French asbestos plant workers from 1978 to 2009. In addition to mesothelioma, the ...
(Date:8/30/2015)... , ... August 30, 2015 , ... ... has been promoted from Administrative assistant to Executive Assistant to CEO Mitch Gould ... a proven professional, focused on your goals. Kathleen graduated from Florida State ...
(Date:8/29/2015)... ... August 29, 2015 , ... On Saturday, September 19, 2015, Diane Blackburn-Zambetti, the ... (Meso Foundation) will present an educational program titled “Asbestos and Your Health.” , The ... PM (doors open at 6:45pm) at Calvary United Methodist Church, 16 E Park Ave., ...
(Date:8/29/2015)... ... August 29, 2015 , ... Brands like Toppik , Eau ... shipping costs. , “Before, a threshold of $49.00 was required to qualify for free ... qualify for free standard shipping for customers regardless of the item’s selling price.” , ...
Breaking Medicine News(10 mins):Health News:ChopChop Kids Appoints New Chair and Vice-Chair to Board of Directors 2Health News:ChopChop Kids Appoints New Chair and Vice-Chair to Board of Directors 3Health News:Researchers Say Mesothelioma Not the Only Cancer Linked with Asbestos Exposure, According to Surviving Mesothelioma 2Health News:NPI Appoints New Executive Assistant To CEO 2Health News:Mesothelioma Applied Research Foundation to Hold Educational Class About Asbestos and Mesothelioma Prevention 2Health News:TheBeautyPlace.com Discounts Shipping on Select Brands 2
... thrombosis linked to deep vein thrombosis, study says , ... condition -- superficial vein thrombosis, or varicose veins that ... presence of a more dangerous problem. , One-quarter of ... study actually had deep vein thrombosis (DVT), a potentially ...
... metastasis, researchers say , MONDAY, July 20 (HealthDay News) ... contribute to aggressive breast cancer, new research shows. , ... of breast cancer tumors, researchers from the Genome Institute ... implicated in the development of breast cancer. , They ...
... , , , ... the "Door to Door" program for patients with multiple myeloma. Cancer Care ,s ... patients for covering transportation costs such as gasoline and taxi, bus or train ... The program is funded in part by a generous grant from ...
... , CBO Announcement Says Current Legislation Does Not ... , WASHINGTON, July 20 In response to a recent ... the Senate and House, the PFCD urges Congress to address the number-one ... , "The Senate HELP and House Ways ...
... School and Amtek, Hanover, NH may treat tumors that do ... on May 29th in the open access, peer reviewed journal ... to selectively kill tumors while protecting healthy cells. In ... as methylthioadenosine phosphorylase (MTAP) is missing in 35 to ...
... one of only four sites across the country to participate ... study will investigate the effectiveness of a chemotherapeutic agent, ThermoDox, ... therapy) for treating recurrent chest wall breast cancer. ... breast cancer on the chest wall, most commonly presenting in ...
Cached Medicine News:Health News:Vein Condition May Mask Serious Clot Disorder 2Health News:New Gene May Signal Aggressive Breast Cancer 2Health News:CancerCare Launches New Program to Help Multiple Myeloma Patients Cover Transportation Costs 2Health News:CancerCare Launches New Program to Help Multiple Myeloma Patients Cover Transportation Costs 3Health News:PFCD Urges Congress to Address Real Cost-Driver in Health Reform in Light of New CBO Statement 2Health News:New strategy in tumor treatment 2Health News:RI Hospital first in country to enroll patient in new study for recurrent chest wall breast cancer 2
(Date:8/27/2015)... , Aug. 27, 2015  A recent study ... Knee Journal, compared the Arthrosurface HemiCAP® Wave implant, ... versus an "onlay" design implant for isolated patellofemoral ... in function and pain scores, none of the ... osteoarthritis (OA). However, 53% of the patients in ...
(Date:8/27/2015)... 27, 2015 ieCrowd™ today announced the ... development of the company,s supplemental oxygen delivery device, ... being developed by ieCrowd,s subsidiary Smart Oxygen Solutions ... demand for oxygen based on level of activity.  ... for the Smart Oxygen device would require a ...
(Date:8/27/2015)... , Aug. 27, 2015  Now that Intuitive ... Da Vinci S™ surgical robot, hospitals with robotic surgery ... They also need to see where they stand with ... the right patients? Have they adopted best practices for ... program in the future? ECRI Institute, which ...
Breaking Medicine Technology:Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 2Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 3Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 2Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 3Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 4ECRI Institute's New Robotic Surgery Service Helps Hospitals Brace for Change 2ECRI Institute's New Robotic Surgery Service Helps Hospitals Brace for Change 3
... Texas, April 8, 2011 Novation, the leading health ... St. Jude Medical (St. Paul, MN) to its portfolio ... St. Jude Medical is a leading provider of ... patients. The company provides a full portfolio of arrhythmia ...
... April 8, 2011 Pacira Pharmaceuticals, Inc. (NASDAQ: ... Scibetta, chief financial officer, is scheduled to present at the ... April 15, 2011, at 11:30 a.m. EDT being held at ... City. Mr. Scibetta is expected to present an overview of ...
Cached Medicine Technology:Novation Announces the Addition of St. Jude Medical to the Cardiac Rhythm Management Products Portfolio 2Pacira Pharmaceuticals to Present at BioCentury Future Leaders in the Biotech Industry Conference 2
Sera available in three levels for the control of accuracy and precision for up to 31 analytes...
Human based material available in two levels for thecontrol of percision for up to 10 analytes...
Human based material available in two levels for the control of accuracy and precision for upto 23 analytes....
Human based assayed sera available in three levels for the control of accuracy and precision for up to 25 analytes...
Medicine Products: